The authors conclude that KRAS mutation status can be used to identify the subgroup of patients with irinotecan-refractory metastatic CRC who are most likely to respond to cetuximab.

KRAS G12D and G12V mutations in pancreatic ductal adenocarcinoma are associated with worse outcomes compared to KRAS wild-type. KRAS G12R mutation is linked to more favorable patient outcomes, with ...

According to the National Cancer Institute's website, KRAS is a gene that makes a protein involved in cell signaling pathways that regulate cell growth, maturation and death. The normal form of the ...

In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than ...

Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...

Verastem's assets, Avutometinib and Defactinib, show promising results in treating KRAS-mutated LGSOC. Read why VSTM stock is a Hold.

Silexion's SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS ...

FDA-approved drugs sotorasib and adagrasib have given new hope to some patients by targeting this KRAS G12C mutation ... FGTI-2734 blocks cancer cells' wild type RAS membrane localization ...

Additionally, xT CDx is approved as a companion diagnostic to identify patients with KRAS wild-type CRC who could be candidates for treatment with cetuximab (Erbitux); and patients with KRAS and ...